semaglutide and cardiovascular outcomes in obesity without diabetes | NEJM 👉 Semaglutide and Cardiovascular Outcomes

A diabetes medication that quickly rose to fame for its weight loss effects has experts exploring how it might help treat everything from heart disease to sleep apnea.Ozempic, Wegovy, and Zepbound, which belong to a group of drugs called GLP-1 receptor agonists, are showing promise in helping manage several long-term health problems.

Large-bowel obstruction (LBO) is an emergency condition that requires early identification and intervention

GLP-1 is a naturally occurring hormone involved in appetite signaling and digestion

Is Retatrutide worth it

For more, check out our full report on Ro (dataset)...

Appetite is changing